Literature DB >> 23942824

Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Dieter Schoepf1, Hardeep Uppal, Rahul Potluri, Reinhard Heun.   

Abstract

Schizophrenia is a major psychotic disorder with significant comorbidity and mortality. Patients with schizophrenia are said to suffer more type-2 diabetes mellitus (T2DM) and diabetogenic complications. However, there is little consistent evidence that comorbidity with physical diseases leads to excess mortality in schizophrenic patients. Consequently, we investigated whether the burden of physical comorbidity and its relevance on hospital mortality differed between patients with and without schizophrenia in a 12-year follow-up in general hospital admissions. During 1 January 2000 and 31 June 2012, 1418 adult patients with schizophrenia were admitted to three General Manchester NHS Hospitals. All comorbid diseases with a prevalemce ≥1% were compared with those of 14,180 age- and gender-matched hospital controls. Risk factors, i.e. comorbid diseases that were predictors for general hospital mortality were identified using multivariate logistic regression analyses. Compared with controls, schizophrenic patients had a higher proportion of emergency admissions (69.8 vs. 43.0%), an extended average length of stay at index hospitalization (8.1 vs. 3.4 days), a higher number of hospital admissions (11.5 vs. 6.3), a shorter length of survival (1895 vs. 2161 days), and a nearly twofold increased mortality rate (18.0 vs. 9.7%). Schizophrenic patients suffered more depression, T2DM, alcohol abuse, asthma, COPD, and twenty-three more diseases, many of them diabetic-related complications or other environmentally influenced conditions. In contrast, hypertension, cataract, angina, and hyperlipidaemia were less prevalent in the schizophrenia population compared to the control population. In deceased schizophrenic patients, T2DM was the most frequently recorded comorbidity, contributing to 31.4% of hospital deaths (only 14.4% of schizophrenic patients with comorbid T2DM survived the study period). Further predictors of general hospital mortality in schizophrenia were found to be alcoholic liver disease (OR = 10.3), parkinsonism (OR = 5.0), T1DM (OR = 3.8), non-specific renal failure (OR = 3.5), ischaemic stroke (OR = 3.3), pneumonia (OR = 3.0), iron-deficiency anaemia (OR = 2.8), COPD (OR = 2.8), and bronchitis (OR = 2.6). There were no significant differences in their impact on hospital mortality compared to control subjects with the same diseases except parkinsonism which was associated with higher mortality in the schizophrenia population compared with the control population. The prevalence of parkinsonism was significantly elevated in the 255 deceased schizophrenic patients (5.5 %) than in those 1,163 surviving the study period (0.8 %, OR = 5.0) and deceased schizophrenic patients had significantly more suffered extrapyramidal symptoms than deceased control subjects (5.5 vs. 1.5 %). Therefore patients with schizophrenia have a higher burden of physical comorbidity that is associated with a worse outcome in a 12-year follow-up of mortality in general hospitals compared with hospital controls. However, schizophrenic patients die of the same physical diseases as their peers without schizophrenia. The most relevant physical risk factors of general hospital mortality are T2DM, COPD and infectious respiratory complications, iron-deficiency anaemia, T1DM, unspecific renal failure, ischaemic stroke, and alcoholic liver disease. Additionally, parkinsonism is a major risk factor for general hospital mortality in schizophrenia. Thus, optimal monitoring and management of acute T2DM and COPD with its infectious respiratory complications, as well as the accurate detection and management of iron-deficiency anaemia, of diabetic-related long-term micro- and macrovascular complications, of alcoholic liver disease, and of extrapyramidal symptoms are of utmost relevance in schizophrenia.

Entities:  

Mesh:

Year:  2013        PMID: 23942824     DOI: 10.1007/s00406-013-0436-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  151 in total

1.  Cardiovascular procedures in patients with mental disorders.

Authors:  J K Young; D A Foster
Journal:  JAMA       Date:  2000-06-28       Impact factor: 56.272

2.  Recording of diabetes on death certificates. Has it improved?

Authors:  J C Will; F Vinicor; J Stevenson
Journal:  J Clin Epidemiol       Date:  2001-03       Impact factor: 6.437

3.  The 100-year epidemiology of schizophrenia.

Authors:  A Jablensky
Journal:  Schizophr Res       Date:  1997-12-19       Impact factor: 4.939

4.  Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; George A Wells; Julio A Chirinos; Li Chen; Michael J Fine
Journal:  Circulation       Date:  2012-01-04       Impact factor: 29.690

5.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

6.  The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia.

Authors:  Finlay A McAlister; Sumit R Majumdar; Sandra Blitz; Brian H Rowe; Jacques Romney; Thomas J Marrie
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

Review 7.  Mortality in schizophrenia.

Authors:  Pascal Auquier; Christophe Lançon; Frédéric Rouillon; Malcolm Lader; Catriona Holmes
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-12       Impact factor: 2.890

8.  Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies.

Authors:  Amanda Nicholson; Hannah Kuper; Harry Hemingway
Journal:  Eur Heart J       Date:  2006-11-02       Impact factor: 29.983

Review 9.  Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists.

Authors:  Richard I G Holt
Journal:  Br J Psychiatry Suppl       Date:  2004-04

Review 10.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

View more
  38 in total

1.  Metagenomic Sequencing Indicates That the Oropharyngeal Phageome of Individuals With Schizophrenia Differs From That of Controls.

Authors:  Robert H Yolken; Emily G Severance; Sarven Sabunciyan; Kristin L Gressitt; Ou Chen; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Lucy A B Schweinfurth; Christina L G Savage; Maria Banis; Sunil Khushalani; Faith B Dickerson
Journal:  Schizophr Bull       Date:  2015-02-09       Impact factor: 9.306

2.  Comorbidity, stigma and emotional perception in psychiatric disorders.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02       Impact factor: 5.270

Review 3.  The microbiome, immunity, and schizophrenia and bipolar disorder.

Authors:  Faith Dickerson; Emily Severance; Robert Yolken
Journal:  Brain Behav Immun       Date:  2016-12-18       Impact factor: 7.217

Review 4.  Is it time for immunopsychiatry in psychotic disorders?

Authors:  Marion Leboyer; José Oliveira; Ryad Tamouza; Laurent Groc
Journal:  Psychopharmacology (Berl)       Date:  2016-03-18       Impact factor: 4.530

5.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

Review 6.  Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia.

Authors:  Monojit Debnath; Michael Berk
Journal:  Mol Neurobiol       Date:  2016-11-29       Impact factor: 5.590

7.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

8.  Socio-environmental factors associated with diabetes mellitus among patients hospitalized with schizophrenia in Japan.

Authors:  Junya Sado; Tetsuhisa Kitamura; Norio Noma; Makiko Saito; Hitoshi Azuma; Tsukasa Azuma; Tomotaka Sobue; Yuri Kitamura
Journal:  Environ Health Prev Med       Date:  2016-07-22       Impact factor: 3.674

9.  Severe mental illness and health service utilisation for nonpsychiatric medical disorders: A systematic review and meta-analysis.

Authors:  Amy Ronaldson; Lotte Elton; Simone Jayakumar; Anna Jieman; Kristoffer Halvorsrud; Kamaldeep Bhui
Journal:  PLoS Med       Date:  2020-09-14       Impact factor: 11.069

10.  Impact of mental illness on care for somatic comorbidities in France: a nation-wide hospital-based observational study.

Authors:  J Gervaix; G Haour; M Michel; K Chevreul
Journal:  Epidemiol Psychiatr Sci       Date:  2018-04-25       Impact factor: 6.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.